Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Do you include the entire seroma in your lumpectomy cavity volume for PBI when it extends far beyond surgical clips?
Answer from: Radiation Oncologist at Community Practice
Yes, as surgical clips can migrate and can’t ignore visible seroma which is part of the surgical bed.
Comments
Radiation Oncologist at Rush University Medical Center
The only time this could be a problem is if the su...
7293
Sign in or Register to read more
14626
Related Questions
Would you offer ultra-hypofractionated accelerated partial breast re-irradiation using 5 fractions?
In patients with history of prior axillary surgery, subsequently with breast cancer recurrence, and sentinel lymph nodes mapped to internal mammary area (but were not biopsied), do you offer post-mastectomy radiation to cover the IMNs?
Is there additional concern for late cardiac toxicity when using ultrahypofractionated breast radiation protocols, given that the BED to the heart is higher?
How would you manage a pT2N1a invasive ductal carcinoma s/p lumpectomy and sentinel lymph node biopsy with ECE, and two mildly avid axillary lymph nodes on post-op PET/CT?
Would you offer prone APBI with IMRT/VMAT?
Do you recommend adjuvant RT to patients with non-ATM genetic mutations (e.g. BRCA, NF) who elect to have lumpectomy and are otherwise PRIME II/CALGB candidates for RT omission (i.e. low risk disease characteristics: strongly ER+, <1cm, grade 1-2, no LVI, widely negative margins, and committed to endocrine therapy)?
How do you approach boost to the lumpectomy cavity AND 4 lymph nodes with extra-nodal extension when treating breast cancer with hypofractionation?
Would you recommend MRI post surgery and pre-irradiation for patients with extensive DCIS and close margins and how would it impact your management?
Does radiation therapy (ex. to the breast) in patients with CDK4 mutations increase the risk of developing melanoma?
How would you manage an isolated nodal recurrence of breast cancer in a patient with a prior history of mantle-field radiation?
The only time this could be a problem is if the su...